Latest Conference Coverage

Reportedly, data from the IMROZ study marks the first time an anti-CD38 monoclonal antibody combined with standard-of-care therapy has demonstrated significant improvement in progression-free survival for newly diagnosed transplant-ineligible multiple myeloma.

After three years of study, the V940 and Keytruda combination demonstrated sustained benefits in recurrence-free survival and distant metastasis-free survival in patients with high-risk melanoma following complete resection.

Results of the ADRIATIC trial indicated that treatment with Imfinzi after standard-of-care concurrent chemoradiotherapy improves overall survival and progression-free survival in patients with limited-stage small cell lung cancer.

Results of the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) show that 100% of participants achieved a clinical complete response when treated with Jemperli for locally advanced rectal cancer in patients with mismatch repair deficient status.

In an interview with Pharm Exec Associate Editor Don Tracy, Tala Fakhouri, at Financial Times’ US Pharma and Biotech Summit, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses whether the FDA plans on restricting the use of AI and what the future could look like when it comes to machine learning.

Experts discuss how new innovations are changing the relationship the industry has with patients.

Experts discuss how attempts to solve the drug pricing problem in the US are working.

In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer, Head of Strategic Initiatives, PhRMA discusses the upcoming United States presidential election and the potential impact that it could have on the pharma industry.

Experts discuss how the upcoming election is impacting the pharma industry, and how either party’s victory could change the landscape in the following years.

KOLs in the sector examine the current dealmaking landscape, including the status of available capital.

In an interview with Pharm Exec Associate Editor Don Tracy, Carmen Villar, VP, ESG & Corporate Citizenship, Gilead Sciences discusses the changes expected in the pharma industry that will come with the entry of younger professionals.

Tala Fakhouri spoke at the conference about FDA’s approach to determining when it even needs to regulate the usage of AI in the pharma industry.

In an interview with Pharm Exec Associate Editor Don Tracy at Financial Times’ US Pharma and Biotech Summit, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses the use of artificial intelligence and machine learning in drug development.

Industry experts gather to discuss the current investor market and how the IRA may impact the industry in the coming years.

Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with somatostatin receptor-positive well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors.

The data was collected during the LEAP clinical program, developed in partnership with Merck.

Ginkgo Bioworks announces projected total revenue of $250–$260 million for 2023 for large scale data generation and artificial intelligence for biopharma R&D.

The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.

Moderna’s vaccine revenue dropped from $18.4 billion in 2022 to $6.7 billion in 2023, however the company anticipates profitability this year powered by COVID-19 vaccine sales and the launch of its mRNA-based respiratory syncytial virus vaccine.

A panel at the recent Talk Health event in Philadelphia focused on what success looks like in audio from publisher, vendor, and HCP perspectives.

In this interview, Arun Thachi, Director, Head of IT Marketing and Sales, Boehringer Ingelheim, discusses the AI journey in pharma.

Stefan Merlo, Vice President, Commercial Development, CSL Seqirus discusses how COVID-19 has evolved the discussion of vaccines and the long-term concerns stemming from flu vaccine fatigue.

Rebecca Vermeulen, VP Global Patient Networks, Product Development Medical Affairs for Roche discusses how they approach patient engagement.

Digital and innovation leader takes issue with the current state of pharma marketing and suggests new approaches are needed.

Industry insights on how pharma is faring in tapping new innovations and approaches in digital health.

Panel discusses what real-world evidence—and related patient-reporting technology—need to achieve to better influence payer decision-making.

Tool highlights efforts to overcome the challenges of remote disease management in Turkey.

Experts explore MA's evolving role and skill set in engaging effectively with clinicians and other external stakeholders.

German laws, European VBCs, and trends in China, Brazil, and Saudi Arabia are changing the way global market access works.

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.